June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Vascular Protective Effects of Candesartan In Ischemic Retinopathy
Author Affiliations & Notes
  • Azza El-Remessy
    Clin & Experimental Therapeutics, University of Georgia, Augusta, GA
    VA Medical Center, Augusta, GA
  • Ahmed Shanab
    Clin & Experimental Therapeutics, University of Georgia, Augusta, GA
    VA Medical Center, Augusta, GA
  • Suraporn Matragoon
    Clin & Experimental Therapeutics, University of Georgia, Augusta, GA
    VA Medical Center, Augusta, GA
  • Susan Fagan
    Clin & Experimental Therapeutics, University of Georgia, Augusta, GA
    VA Medical Center, Augusta, GA
  • Footnotes
    Commercial Relationships Azza El-Remessy, None; Ahmed Shanab, None; Suraporn Matragoon, None; Susan Fagan, Pfizer, Inc (C), Astra Zeneca (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4538. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Azza El-Remessy, Ahmed Shanab, Suraporn Matragoon, Susan Fagan, ; Vascular Protective Effects of Candesartan In Ischemic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4538.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Ischemic retinopathy including retinopathy of prematurity (ROP) and diabetic retinopathy is characterized by impaired reparative angiogenesis and accelerated pathological neovascularization. The aim of this study is to examine whether the angiotensin receptor blocker (ARB) candesartan can improve angiogenic response in ROP model by selectively enhancing physiological angiogenesis and inhibiting pathological angiogenesis.

Methods: ROP was induced by exposing neonatal mice along with their dam to 70% oxygen (hyperoxia) from postnatal day p7 to p12. The pups were brought back to room air (relative hypoxia) and treated with candesartan (10mg/Kg/day, IP) from p12 to p17 (21% oxygen). Retinal vascular density was assessed by isolectin-B4 staining. Peroxynitrite formation and expression of VEGF, iNOS, eNOS, heamoxygenase-1 (HO-1), were assessed by slot-blot, real-time PCR and Western Blot analyses. Glial Muller activation was assessed using immunohistochemistry.

Results: Candesartan decreased the pathological peripheral neovascularization by 70% and improved physiological revascularization of central retina by 45% compared to untreated pups. Hypoxia-induced significant retinal nitrative stress as indicated by nitrite formation (4.2-fold) and nitrotyrosine formation (4.6-fold). These effects were associated with increases in iNOS (2-fold), eNOS (1.6-fold), VEGF (2-fold) but no change in HO-1expression. Treatment with candesartan during hypoxia (p12-p17) completely abrogated nitrative stress, significantly reduced iNOS expression, stimulated HO-1 expression (5-fold) while maintained VEGF and eNOS expression. In parallel, candesartan induced expression of VEGF, eNOS and HO-1 at the mRNA level. Hypoxia-induced glial activation as indicated by radial GFAP was significantly reduced in candesartan-treated animals. Under normoxia, candesartan treatment stimulated expression of VEGF (1.4-fold), eNOS (2-fold) and HO-1 (3-fold) compared to untreated pups.

Conclusions: Candesartan improved reparative angiogenesis and prevented pathological angiogenesis in ischemic retinopathy model. The results suggest a mechanism that involves reducing oxidative and nitrative stress via modulating iNOS and HO-1 expression without altering VEGF levels.

Keywords: 617 nitric oxide • 609 neovascularization • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×